X4 Pharmaceuticals (XFOR) Return on Sales (2018 - 2025)
Historic Return on Sales for X4 Pharmaceuticals (XFOR) over the last 7 years, with Q3 2025 value amounting to 16.89%.
- X4 Pharmaceuticals' Return on Sales rose 486400.0% to 16.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.8%, marking a year-over-year increase of 121300.0%. This contributed to the annual value of 14.4% for FY2024, which is N/A changed from last year.
- Per X4 Pharmaceuticals' latest filing, its Return on Sales stood at 16.89% for Q3 2025, which was up 486400.0% from 13.05% recorded in Q2 2025.
- In the past 5 years, X4 Pharmaceuticals' Return on Sales registered a high of 161.34% during Q2 2024, and its lowest value of 65.53% during Q3 2024.
- Over the past 4 years, X4 Pharmaceuticals' median Return on Sales value was 22.38% (recorded in 2022), while the average stood at 23.92%.
- Per our database at Business Quant, X4 Pharmaceuticals' Return on Sales surged by 1214700bps in 2024 and then crashed by -1743800bps in 2025.
- Over the past 4 years, X4 Pharmaceuticals' Return on Sales (Quarter) stood at 25.44% in 2022, then skyrocketed by 259bps to 91.22% in 2023, then plummeted by -130bps to 26.96% in 2024, then soared by 37bps to 16.89% in 2025.
- Its Return on Sales stands at 16.89% for Q3 2025, versus 13.05% for Q2 2025 and 0.01% for Q1 2025.